News

The U.S. Food and Drug Administration (FDA) has approved Yuflyma (adalimumab-aaty), a high concentration biosimilar of Humira (adalimumab), for the treatment of ankylosing spondylitis. Other approved indications for Yuflyma are rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. According…

Anxiety and depression, but not resilience, were found to be linked to poorer overall health and functioning in people with axial spondyloarthritis (axSpA) — mostly men and almost all Chinese — who took part in a study done by researchers in Singapore. “Clinicians could consider routinely screening for anxiety and…

Proteins associated with inflammation and immune system function were identified as potential blood biomarkers for the diagnosis and monitoring of ankylosing spondylitis (AS). “Better biomarkers would address a significant unmet need both in clinic, where earlier diagnosis and referral might be improved, as well as in bettering our understanding…

Ankylosing spondylitis (AS) patients undergoing total hip replacement face longer hospital stays and higher related costs than other patients after the surgery, according to an analysis of hospital records. More complications, including anemia and infections, soon after surgery drove these increases in stays and admission-related costs, researchers noted. These…

The first patient has been randomized in a pivotal Phase 3 program testing oral filgotinib in adults with active axial spondyloarthritis (AxS), including ankylosing spondylitis (AS). The OLINGUITO program (NCT05785611) consists of two placebo-controlled, parallel clinical trials into the safety and efficacy of filgotinib in adults with…

One year of treatment with Cosentyx (secukinumab) showed safety and efficacy in a real-world study conducted in Italy, lowering disease activity among people with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Men were overall more likely than women to achieve disease remission after a year of treatment. “This…

People with ankylosing spondylitis (AS) are at a significantly higher risk of stroke — a 56% greater risk — than those without this disease, according to a pooled analysis of 11 published studies involving more than 1.7 million participants. Management of stroke risk factors and control of systemic (bodywide)…

Machine learning methods may help in the early detection of ankylosing spondylitis (AS), a new study reported. “It’s fantastic to see the cutting-edge role that machine learning can play in the early identification of patients with health conditions such as AS … Though it is in its early stages,…

When combined with modern evidence-based medicine, treatment with the traditional Chinese herbal medicine Duhuo Jisheng decoction may help relieve pain and improve mobility in people with ankylosing spondylitis (AS), according to an analysis of clinical trial data. “Current evidence suggests that [Duhuo Jisheng decoction] combined with Western medicine is…

A high concentration formulation of Sandoz’s biosimilar Hyrimoz (adalimumab-adaz) has been approved by the U.S. Food and Drug Administration (FDA) to treat ankylosing spondylitis (AS) and other conditions. The new citrate-free formulation (100 mg/mL) is expected to be available on July 1, according to Sandoz. It’s approved for seven…